The conference programme consists of world-class keynote addresses, industry and academic led presentations, as well as ample networking opportunities, creating an interactive platform for high-level scientific and business discussions.
Over 250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions.
Over 20 presentations and case studies focused on the key issues in cell & gene therapy development, updates in regulatory pathways, commercialisation, bioprocessing and manufacturing.
2 interactive streams:
- Cell & Gene Therapy: Development, Clinical Trials & Commercialisation
- Cell Therapy Bioprocessing and Manufacturing
Co-located with the established 5th Annual Cell Culture & Bioprocessing Congress and 3rd Annual Stem Cell Congress.
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities.
Cell and gene therapy is an increasingly exciting field for the pharmaceutical industry, more recently referred to as experiencing a 鈥榗omeback era鈥�. Experts have forecasted that the overall market for gene therapies will reach $204m in 2020. Significant medical advances have been made which have in turn, also highlighted challenges for future cell and gene therapy research, funding limitations and the strict regulatory guidelines imposed. There is now a specific focus on accelerating clinical development and overcoming common pitfalls in this process that have previously been made. Accumulated clinical data and successful case studies have meant that cell and gene therapy is now becoming a reality for researchers, set to transform the future of disease treatment.
Day one of the congress will focus on development, clinical trials & commercialisation of cell and gene therapies. Delegates will have the opportunity to hear future challenges of advanced therapies including evolving regulatory requirements, reimbursement and the transfer of cell therapies into commercial products. A recent hot topic to be discussed at the conference focuses on Japanese regulatory frameworks for developing cell-based therapies, in comparison to US and European approaches. In addition to this, our expert speakers will discuss optimal assay development and validation for cell therapies.
Day two of the congress will focus on cell therapy bioprocessing and manufacturing challenges. Representatives from leading cell and gene therapy industry organisations will provide exciting case studies discussing the production of autologous and allogenic cellular therapies, CAR-/TCR approaches, upstream & downstream processing and scale-up. Novel vector systems for gene therapy and vaccines also will be discussed by experts who are at the forefront of the field, as well as overcoming challenges in genetically modified T-cell immunotherapy manufacture.
Over 250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions.
Over 20 presentations and case studies focused on the key issues in cell & gene therapy development, updates in regulatory pathways, commercialisation, bioprocessing and manufacturing.
2 interactive streams:
- Cell & Gene Therapy: Development, Clinical Trials & Commercialisation
- Cell Therapy Bioprocessing and Manufacturing
Co-located with the established 5th Annual Cell Culture & Bioprocessing Congress and 3rd Annual Stem Cell Congress.
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities.
Cell and gene therapy is an increasingly exciting field for the pharmaceutical industry, more recently referred to as experiencing a 鈥榗omeback era鈥�. Experts have forecasted that the overall market for gene therapies will reach $204m in 2020. Significant medical advances have been made which have in turn, also highlighted challenges for future cell and gene therapy research, funding limitations and the strict regulatory guidelines imposed. There is now a specific focus on accelerating clinical development and overcoming common pitfalls in this process that have previously been made. Accumulated clinical data and successful case studies have meant that cell and gene therapy is now becoming a reality for researchers, set to transform the future of disease treatment.
Day one of the congress will focus on development, clinical trials & commercialisation of cell and gene therapies. Delegates will have the opportunity to hear future challenges of advanced therapies including evolving regulatory requirements, reimbursement and the transfer of cell therapies into commercial products. A recent hot topic to be discussed at the conference focuses on Japanese regulatory frameworks for developing cell-based therapies, in comparison to US and European approaches. In addition to this, our expert speakers will discuss optimal assay development and validation for cell therapies.
Day two of the congress will focus on cell therapy bioprocessing and manufacturing challenges. Representatives from leading cell and gene therapy industry organisations will provide exciting case studies discussing the production of autologous and allogenic cellular therapies, CAR-/TCR approaches, upstream & downstream processing and scale-up. Novel vector systems for gene therapy and vaccines also will be discussed by experts who are at the forefront of the field, as well as overcoming challenges in genetically modified T-cell immunotherapy manufacture.
